Business Context and Reporting Period
This Form 8-K Current Report is filed by BioSig Technologies, Inc. (not Streamex Corp.) for the reporting period of February 21, 2020. The registrant is a Delaware corporation with principal executive offices in Westport, Connecticut, and its common stock trades on the NASDAQ Capital Market under the symbol BSGM.
Key Financial Metrics and Transaction Details
The filing details a material definitive agreement regarding an underwritten public offering of common stock. Key financial terms include:
- Shares Offered: 2,500,000 shares of Common Stock.
- Public Offering Price: $4.00 per share.
- Underwriter Purchase Price: $3.68 per share.
- Expected Net Proceeds: $9,200,000 (after underwriting discount, before offering expenses).
- Underwriter Warrants: Warrants to purchase up to 125,000 shares (5% of shares sold) at an exercise price of $4.80 per share (120% of public offering price).
- Expense Reimbursement: Up to $100,000 for the underwriter's out-of-pocket expenses.
The filing text does not provide clear values for the company's historical revenue, profit, cash flow, margins, or existing debt levels, as this report focuses solely on the equity offering.
Material Changes and Transaction Structure
The primary material change is the entry into an underwriting agreement with Laidlaw & Company (UK) Ltd. on February 21, 2020. The offering is structured on a "best efforts" basis, meaning the underwriter has no obligation to purchase any specific number of shares. The transaction utilizes a shelf registration statement (No. 333-230448) declared effective on March 29, 2019. The offering was expected to close on or about February 25, 2020.
Guidance, Outlook, and Risks
Management Commentary and Outlook: The company issued press releases on February 20 and February 21, 2020, announcing the proposed offering and its pricing, respectively. The proceeds are intended to support the company's operations, though specific allocation details are not provided in this text.
Risks and Contingencies:
- Best Efforts Basis: There is no guarantee that the full 2,500,000 shares will be sold, as the underwriter is not obligated to purchase a specific amount.
- Closing Conditions: The transaction is subject to the satisfaction of customary closing conditions.
- Dilution: The issuance of new shares and the grant of underwriter warrants will result in dilution to existing shareholders.
Investor Verification Checklist
- Verify the final closing date and the actual number of shares sold, given the "best efforts" nature of the agreement.
- Confirm the total offering expenses deducted from the $9,200,000 expected net proceeds.
- Review the full text of the Underwriting Agreement (Exhibit 1.1) for specific termination provisions and indemnification details.
- Check subsequent filings to confirm the use of proceeds and any changes to the company's capital structure post-closing.